Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Parkinson Disease in United States

252 results

Sort By:

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

Study ID: NCT06377033
Start Date: 2024-06-10
End Date: 2027-06-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

1000

Intervention / Treatment

Behavioral nudge

Sponsor

University of Pennsylvania

Source: clinicaltrials.gov

Share:
Add to list

Vibrotactile Coordinated Reset: a Non-invasive Treatment for Parkinson's Disease 2

Study ID: NCT05881460
Start Date: 2023-07-12
End Date: 2026-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

30

Intervention / Treatment

Active vibrotactile coordinated reset

Sham vibrotactile coordinated reset

Sponsor

Synergic Medical Technologies, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Modifiable Variables in Parkinsonism (MVP)

Study ID: NCT02194816
Start Date: 2012-09
End Date: 2030-12
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

2000

Intervention / Treatment
Sponsor

Bastyr University

Source: clinicaltrials.gov

Share:
Add to list

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Study ID: NCT06976268
Start Date: 2025-05-28
End Date: 2027-09
Study Type

Interventional

Study Phase

Phase3

No. of Participants

550

Intervention / Treatment

BHV-8000

BHV-8000

Placebo

Sponsor

Biohaven Therapeutics Ltd.

Source: clinicaltrials.gov

Share:
Add to list

Imaging Depression in Parkinson's Disease

Study ID: NCT06402955
Start Date: 2024-09-01
End Date: 2029-12-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

120

Intervention / Treatment

11C-UCB-J

ketamine hydrochloride

Sponsor

Yale University

Source: clinicaltrials.gov

Share:
Add to list

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Study ID: NCT06312176
Start Date: 2024-04-14
End Date: 2031-04-12
Study Type

Interventional

Study Phase

Phase3

No. of Participants

1200

Intervention / Treatment

Sacituzumab tirumotecan

Pembrolizumab

Paclitaxel

Nab-paclitaxel

Capecitabine

Liposomal doxorubicin

Sponsor

Merck Sharp & Dohme LLC

Source: clinicaltrials.gov

Share:
Add to list

rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease

Study ID: NCT06237868
Start Date: 2024-05-01
End Date: 2026-05
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

rTMS Active

rTMS Sham

Sponsor

West Virginia University

Source: clinicaltrials.gov

Share:
Add to list

Remote Dynamic Cycling for the Customized Off-site Rehab in Parkinson's Disease

Study ID: NCT05298150
Start Date: 2022-04-01
End Date: 2026-04-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

72

Intervention / Treatment

Dynamic cycling

Forced cycling

Sponsor

VA Office of Research and Development

Source: clinicaltrials.gov

Share:
Add to list

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Study ID: NCT02071134
Start Date: 2014-03-04
End Date: 2038-12
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

1500

Intervention / Treatment

Deep Brain Stimulation (DBS)

Sponsor

Boston Scientific Corporation

Source: clinicaltrials.gov

Share:
Add to list

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Study ID: NCT06788912
Start Date: 2025-03-20
End Date: 2032-02-06
Study Type

Interventional

Study Phase

Phase2

No. of Participants

60

Intervention / Treatment

Pembrolizumab (neoadjuvant)

Cisplatin

Gemcitabine

Pemetrexed

Sacituzumab tirumotecan

H1 receptor antagonist

H2 receptor antagonist

Acetaminophen (or equivalent)

Dexamethasone (or equivalent)

Carboplatin

Pembrolizumab (adjuvant)

Paclitaxel

Steroid mouthwash (dexamethasone or equivalent)

Sponsor

Merck Sharp & Dohme LLC

Source: clinicaltrials.gov

Share:
Add to list